Recruiting Angelman Syndrome Studies in Chicago
REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome
The purpose of this study is to evaluate the efficacy and safety of ION582 in children and adults with Angelman syndrome caused by a deletion or mutation of the UBE3A gene....
HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome
The purpose of this study is to evaluate the safety and tolerability of ascending doses of ION582 administered intrathecally in participants with Angelman syndrome....
About Angelman Syndrome Clinical Trials in Chicago
Angelman syndrome is a rare genetic disorder primarily affecting the nervous system, characterized by severe developmental delays, speech impairment, seizures, and a happy demeanor. It is caused by loss of function of the UBE3A gene. Treatment focuses on managing symptoms and maximizing developmental potential.
There are currently 2 angelman syndrome clinical trials recruiting participants in Chicago, IL. These studies are seeking a combined 280 participants. Research is being sponsored by Ionis Pharmaceuticals, Inc.. Clinical trial participation is free and participants receive study-related medical care at no cost.
Angelman Syndrome Clinical Trials in Chicago — FAQ
Are there angelman syndrome clinical trials in Chicago?
Yes, there are 2 angelman syndrome clinical trials currently recruiting in Chicago, IL. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Chicago?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Chicago research site will contact you about next steps.
Are clinical trials in Chicago free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Chicago studies also compensate for your time and travel.
What angelman syndrome treatments are being tested?
The 2 active trials in Chicago are testing new therapies including novel drugs, biologics, and treatment approaches for angelman syndrome.
Data updated March 2, 2026 from ClinicalTrials.gov